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When the organisers of the RVH Bicentenary kindly
approached some expatriate "old boys", inviting us to
talk at the celebratory meeting, our brief as we
approached retirement was to review some aspect of
our professional work. I opted to focus on gallstones
and initially, was tempted to begin by reminiscing
about our studies of bile lipid composition in patients
with ileal disease or resection' and our use of the
steady-state secretion perfusion technique2'3 to
measure the hour-by-hour output of biliary lipids in
control subjects and gallstone patients - with
particular emphasis on obesity.4 I might also have
recalled our work on gallbladder motor dysfunction in
gallstone disease5 or our early studies in the use of
chenodeoxycholic6-8 and ursodeoxycholic acids9-1" as
oral treatment for the dissolution of gallstones in
symptomatic patients.
In their day, each of these chapters held its own
fascination and the research fellows who worked on
these projects made valuable contributions to the
literature. But rather than wallow in nostalgia, I have
chosen to review, briefly, the results ofexciting recent
studies, performed by my colleagues at Guy's, over
the past five years. They began with a collaborative
study of acromegalic patients treated with octreotide
who develop iatrogenic gallstones'2 - a phenomenon
well known at the RVH since one of the first
observations on this topic was made by McKnight and
colleagues from the Metabolic Unit ofthe RVH.'3
We are now close to making the "outrageous
assertion" thatcholesterol cholelithiasis is an intestinal
disease,'4 secondary to changes in large bowel transit.'5
This chapter reviews the evidence behind this
assertion and, in keeping with the theme of the
meeting, the chapter ends with a discussion of
strategies for preventing gallstone formation, in the
next millennium.
Clinical Science ofGallstone Formation
The types and composition of gallbladder stones
(GBS) are discussed briefly before the classical theory
of cholesterol (CH) GBS formation is reviewed. This
suggests that, before stones can form, at least three
abnormalities (the so-called triple defect)'6 must co-
exist: (i) supersaturated GB bile, (ii) abnormal
nucleation of CH microcrystals and (iii) stasis due to
impaired GB emptying and/or crystal trapping by
mucus on the surface of the GB mucosa. However,
most of this presentation is based on a modem-day
detective story (still evolving) which describes why
GBS develop in many acromegalic patients treated






Fig I Reported incidence ofgallbladder stones (GBS) in
acromegalicpatients treated with octreotide (OT) in doses
rangingfrom 100-1500 ug /dayforperiods rangingfrom 3-70
mo. (Mostpatients received 100-200 ug tds by sub-cutaneous
injection,forapproximately 1-2 yr). Since at the start ofOT
treatment thesepatients werefree ofGBS by ultrasound, the
results ofthese 18 studies represent thefrequency ofOT-induced
(rather than OT-associated) GBS. The vertical bars represent the
percentage ofpatients developing cholelithiasis: the numbers at
the top ofthe columns refer to the numbers ofpatients developing
stones, over the numbers ofpatients treated. The broken
horizontal line represents the mean incidence ofOT-induced
stones (29%) in these 18 studies.
OT is an effective treatment for acromegaly. It acts by
suppressing growth hormone and insulin like growth
factor-I levels but it also inhibits meal-stimulated
cholecystokinin release and GB contraction. We
confirmed that OT virtually paralyses the gallbladder'7
but, given the triple defect theory ofGBS formation,16
the first step was to see if OT also affected bile
composition and physical chemistry.
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Step 1
Studies of fresh GB bile from acromegalic patients
with OT-GBS'8 showed that they all have: (i)
supersaturated bile, (ii) a high proportion of their
biliary CH present in unstable vesicles, and (iii)
abnormally rapid nucleation (precipitation) of CH
microcrystals. These changes were associated with,
and may well be due to, excess biliary deoxycholic
acid (DCA % of total bile acids)."8 The hydrophobic
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Fig 2 Schematicflow diagram to explain how an increase in the
percentage ofdeoxycholic acid (%DCA) in bile might lead to an
increased incidence ofcholesterol gallbladder stones (CHGBS).
Thus, enrichment ofbile with DCA leads to a relative increase in
biliary cholesterol secretion (secrn).'9 This may explain why we,20
and others 33'34find that there is a significant linear relationship
between the %oDCA in bile and: (I) the molarpercentage (moles %)
cholesterol and (II) the cholesterol saturation index (SI), in
gallbladder bile. It may also explain, at least inpart, why wefind
that the mean %oDCA in bile is approximately twice as high in
patients with abnormally rapid (< Sd) nucleation orprecipitation of
cholesterol microcrystals, as in individuals with normal (> 10 d)
nucleation times20.
We35 andothers3&s3 also showed that the %DCA in bile was linearly
related to the % arachidonic acid-richphospholipids (AAPL) in bile.
In turn, this may explain40 why mucus glycoprotein (MGP) synthesis
by, andsecretion into, the gallbladder are increased in gallstone
patients4143. An increase in theproportion ofAAPLs in GB bile
could also contribute to the reduced meal-stimulated gallbladder
emptying5"46 which characterises cholesterol gallstone disease.
excess, DCA induces biliary cholesterol
hypersecretion and supersaturation.'9'20 Our results
suggest that the increased biliary DCA seen in OT-
treated acromegalics is due to the somatostatin
analogue treatment, and notto the stones. Thus paired,
before-and-during treatment, studies showed that
within weeks, OT doubled the percent DCA in bile
and induced biliary CH supersaturation - even in the
absence of stones.'8
Step 2
The next step was to determine why OT treatment
doubles the % DCA in bile. Previous studies in control
subjects had suggested that OT prolongs small bowel
transit.21-23 But would it do the same thing in
acromegalics? And, more important, would it also
affect large bowel transit (ofimportance since DCA is
formed in the caecum andproximal colon - rather than
in the small intestine)?
We confirmed that OT markedly prolongs small bowel
transit both in control subjects and in acromegalic
patients.'7 We also showed, again in paired before-
and-during treatment studies,24 that OT significantly
prolongs large bowel transit time (LBTT).
Furthermore, we found that LBTT was linearly related
to: (i) the % DCA in serum25(and, by implication, in
bile), (ii) the DCA pool size26 and (iii) the DCA
formation (or "synthesis") rate.26
Step 3
If prolonged intestinal transit and altered DCA
metabolism play a major role in the pathogenesis of
the exotic OT-induced GBS, could these factors also
play a similar role in "conventional" GBS disease -
that this, GBS unrelated to acromegaly or OT
treatment? The results of our own,4'27 and other,28-30
studies suggest that they do. Indeed, as noted above,
we have even suggested that cholelithiasis is a disease
ofprolonged large bowel transit.'4
Step 4
The mechanism whereby prolongation of intestinal
transit increases the percentage of DCA in serum and
bile, raises several questions. Does prolonged LBTT
increase DCA formation by increasing the number of
anaerobic bacteria in the rightcolon? Does it affect the
activity of their deconjugating and dehydroxylating
enzymes (cholylglycine hydrolase and 7-alpha
dehydroxylase) which produce unconjugated (newly-
formed) DCA from the glycine and taurine conjugates
of cholic acid? Does prolongation of LBTT affect
colonic luminal pH - thereby increasing the solubilis-
ation and bioavailability of the newly-formed DCA?
Or does a longer than normal LBTT allow more time
for DCA absorption from the colon (presumably by
passive non-ionic diffusion)?
The answer to these rhetorical questions seems to be -
yes, yes and yes.'4 By comparison with "controls",
patients with conventional GBS have: (i) significantly
prolonged LBTT, (ii) significantly more total
anaerobes in the caecum and right colon, (iii)
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significantly more gram positive anaerobes, (iv) more
deconjugating (p>0.05) and 7 alpha-dehydroxylating
(p<O.OO5) enzymes per bacterium (or more correctly,
per mg protein in the caecal aspirates), (v) a
significantly greater colonic luminal pH3" (probably
because the prolonged transit allows more time for
absorption of the acidic short chain fatty acids) and,
again, (vi) a significant increase in the %DCA in
fasting serum.
Thus, there is an intriguing web of complex
interactions whereby prolongation of LBTT favours
increased DCA: (i) formation, (ii) solubilisation/
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Fig 3 Flow diagram summarising the results ofseveral studies
from the authors department'6'"2-7' 31,32 showing how
prolongation oflarge bowel transit might increase theproportion
ofdeoxycholic acid (DCA) in the bile acidpool, and in serum
and bile. Thus, an increase in large bowel transit timefavours an
increase in the numbers ofGrampositive (+ve) anaerobes in the
proximal colon. This increase in the numbers ofanaerobes leads
to increases in the total amounts (masses) ofthe intestinal
bacterial bile acid metabolising enzymes responsiblefor
deconjugation (cholylglycine hydrolase: CGH) and 7a-
dehydroxylation (7ca-dehydroxylase: 7ac- DH) ofthe conjugated
bile acids, in the caecum and colon. The resultant increase in
deconjugation means that more cholic acid (CA) isformed in the
proximal colon and this, in turn, may increase the specific
activity (spec act) of7a-DH.
The combination ofincreased total amounts of7a-DHand
increased 7a-DH specific activity, favours enhanced DCA
formation. At the same time, theprolongation in large bowel
transit time increases colonic lummalpHwhich ensures that the
newly-formed unconjugated DCA is solubilised in, and is
therefore made bioavailableforpassive non-ionic (n.i.) diffusion
from, the colon. This expands theproportion ofDCA in the bile
acidpool which is in dynamic equilibrium with the %oDCA in
serum and bile. The consequences ofincreasedproportions of
DCA in bile are summarised in Fig 2.
Step 5
If prolonged colonic transit really is important in the
development of GBS, can all the resultant
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abnormalities be prevented or reversed, by the use of
commonly-prescribed prokinetic drugs which
accelerate intestinal transit? Again, the answer seems
to be yes. In aprospective, random-allocation, double-
blind, crossover design, controlled trial, we showed
thatthe 5HT4 agonist, cisapride, completely prevented
the prolongation ofboth small and large bowel transit
seen in acromegalic patients treated with OT. More
important, cisapride "normalised" the % DCA in
fasting serum.32 Itremains tobe proven, in prospective
controlled trials, that the use of colonic prokinetic
drugs, such as cisapride, can prevent cholesterol GBS
formation in high-risk groups.
This, then, is the challenge for clinical investigators
studying gallstone pathogenesis who, as we look
BACKWARDS in this century, moved from "the
bedside to the bench". As we move FORWARDS to
the year 2000, they must now put this process into
reverse and translate scientific theory into the clinical
practice ofgallstone prevention.
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